is glp 1 safe for kidney disease GLP-1 agonists in the treatment of chronic in type 2 diabetes and obesity There's more and more buzz

The adverse reactions that occurred in placebo-controlled clinical trials in at least 2% of patients treated with amlodipine and valsartan but at a higher incidence in amlodipine/valsartan patients (n=1437) than placebo (n=337) included peripheral edema (5.4% vs 3%), nasopharyngitis (4.3% vs 1.8%), upper respiratory tract infection (2.9% vs 2.1%) and dizziness (2.1% vs 0.9%)

& Borner, G

they are receptor agonists, meaning that they work by binding to the GLP-1 receptors in the brain and body

MedVi takes a more clinical approach the focus is on the provider-patient relationship rather than peer community

136E359E386

Kastenmller are co-inventors (through Duke University/Helmholtz Zentrum Mnchen) on patents on applications of metabolomics in diseases of the central nervous system and hold equity in Chymia LLC and IP in PsyProtix and Atai that are exploring the potential for therapeutic applications targeting mitochondrial metabolism in treatment-resistant depression